Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response.

Pharmacotherapy - 1 Jan 2000

Sowinski K M, Burlew B S

Abstract excerpt

We conducted an open-label study to determine the impact of cytochrome P-4502D6 (CYP2D6) on propranolol pharmacokinetics and response in 12 healthy men with CYP2D6 extensive metabolizer (EM) phenotype and 3 healthy men with CYP2D6 poor metabolizer (PM) phenotype. Subjects received R,S-propranolol hydrochloride 80 mg every 8 hours for 16 doses. After the sixteenth dose, blood and urine samples were collected for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Biotransformation
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Half-Life

Share to Heart Rate

Share to Hydroxylation

Share to Phenotype

Source

Identifiers

PMID: 9399616

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response.PMID 9399616Read ↗

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.Semantic proximity Read ↗

Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.Semantic proximity Read ↗

The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.Semantic proximity Read ↗

CYP2D6 phenotype determines pharmacokinetic variability of propafenone enantiomers in 16 HAN Chinese subjects.Semantic proximity Read ↗

Effect of CYP2D6 Poor Metabolizer Phenotype on Stereoselective Nebivolol Pharmacokinetics.Semantic proximity Read ↗

Effect of CYP2D6 genetic polymorphism on peak propafenone concentration: no significant effect of CYP2D6*10.Semantic proximity Read ↗

Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.Semantic proximity Read ↗

Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate.Semantic proximity Read ↗

Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.Semantic proximity Read ↗

Propranolol disposition in Chinese subjects of different CYP2D6 genotypes.Semantic proximity Read ↗

CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.